Tirzepatide (Mounjaro / Zepbound) in Naperville, IL

Tirzepatide is the active ingredient in Mounjaro and Zepbound. It is a dual agonist that activates two gut-hormone receptors — GIP and GLP-1 — at once, while semaglutide (Ozempic/Wegovy) activates the GLP-1 receptor alone. Both are once-weekly injections used for weight management, and we offer both at our Naperville clinic. The best choice for you is determined by your clinician based on your health history, tolerability, and goals; results vary.

Yes. Under the brand name Zepbound, tirzepatide is FDA-approved for chronic weight management in eligible adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) who also have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The same molecule is sold as Mounjaro, which is FDA-approved for type 2 diabetes.

In the head-to-head 72-week SURMOUNT-5 trial of adults with obesity without diabetes, tirzepatide reduced body weight by an average of about 20.2% versus 13.7% for semaglutide. In SURMOUNT-2 (adults with obesity/overweight and type 2 diabetes), tirzepatide achieved up to about 15.7% at 72 weeks. These are trial averages — your individual results depend on your starting weight, the dose reached, adherence, diet, and activity, and no specific result is guaranteed.

Tirzepatide is a once-weekly subcutaneous injection. Per FDA labeling, treatment begins at 2.5 mg weekly to help your body adjust, then increases in 2.5 mg steps no sooner than every 4 weeks. Common maintenance doses are 5, 10, or 15 mg weekly, with a maximum of 15 mg. Your exact dose and titration pace are individualized and determined by your clinician.

The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — and they are usually most noticeable during dose increases and tend to ease over time. In the Zepbound trials, nausea occurred in roughly 25–29% of patients. Our gradual titration protocol is designed to reduce these effects. Contact us promptly if you have severe or persistent vomiting, signs of dehydration, or severe abdominal pain.

Tirzepatide is contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and for anyone with a serious allergy to tirzepatide or its ingredients. It should not be used during pregnancy. The label also warns about pancreatitis, gallbladder disease, low blood sugar, kidney concerns, and reduced effectiveness of oral birth control pills. We screen for all of these factors before prescribing; final eligibility is determined by your clinician.

Our tirzepatide program is priced by dose tier — Basic (up to 50 units), Advance (50–75 units), and Elite (75–100 units) — and by commitment length, where a longer program lowers your monthly rate. It ranges from $409/month on the Basic 6-month plan ($2,454 total, which includes 24 injections plus 6 PHYSIQ 360 sessions) up to $539/month for Elite month-to-month. Your clinician determines the appropriate dose after your evaluation. For comparison, our semaglutide program starts at $249/month on a 6-month plan. Insurance coverage for weight-management medications varies by plan, and our team can help you review your options. Call (877) 885-8784.